Harvest Technologies Announces Patient Education Website, www.CLIclinicalstudy.com : Supports first randomized, placebo-controlled clinical trial in the U.S. using autologous adult stem cells to treat patients with end-stage Critical Limb...( Harvest Tech...),Health

Harvest Technologies Corp. (www.harvesttech.com) announced today that its new patient-education website, www.CLIclinicalstudy.com, is now “live”. The site is intended to offer persons who are considering enrolling in the Company’s clinical trial and their referring physicians important information related to the study’s design, the science that underlies it, and the location of the study’s sites.

PLYMOUTH, Mass. (Business Wire EON) October 28, 2008 -- The Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to Harvest Technologies to conduct a randomized, controlled, double-blind, multicenter clinical trial using the Company's BMAC System to prepare a composition of bone marrow stem cells to treat patients with Critical Limb Ischemia (CLI). This "feasibility trial" will enroll a total of 48 subjects. Subjects who enroll in this study have exhausted all surgical and procedural options and are at extreme risk for major amputation. The BMAC System is a point-of-care device for concentrating a patient's own (autologous) bone marrow stem cells in approximately 15 minutes at the bedside. The clinical study design provides for injecting these cells into the affected limb to reduce the potential for limb amputation. It also will offer data with respect to the safety of this procedure.

This U.S. clinical study is being led by Principal Investigator Mark D. Iafrati, M.D., Chief of Vascular Surgery at Tufts Medical Center, Boston. In addition, the CLI Study is also enrolling subjects at: Roper St. Francis Healthcare, Charleston, S.C.; Methodist Hospital, Houston; University of South Florida Health, Tampa, Fla.; Maimonides Medical Cen
'/>"/>